Showing 1,821 - 1,840 results of 43,662 for search '(( 5 ((nn decrease) OR (mean decrease)) ) OR ( a ((point decrease) OR (fold decrease)) ))', query time: 0.67s Refine Results
  1. 1821
  2. 1822
  3. 1823
  4. 1824
  5. 1825
  6. 1826
  7. 1827
  8. 1828

    <strong>Figure 2 Manipulation of actin filament dynamics does not impact the decrease in the ATP/ADP ratio or ATP level induced by blockade of ATP production in either growth cones... by Sabrina Holland (16557051)

    Published 2023
    “…<p> The growth cone was defined as the distal 10 microns of the axon shaft. If a growth cone exhibited lamellipodia then the distal most extent of the lamellipodium was taken as the distal most point on the growth cone, if not the distal most extent of the axon shaft was used as the defining distal point. …”
  9. 1829

    Estimated marginal means for changes in outcome parameters A, B, C, D. by Benjamin Udoka Nwosu (476930)

    Published 2015
    “…<p>A. Hemoglobin A1c: Over the course of our 9 months of observation, the between-treatment differences in HbA1c of 0.4% (9.85% [8.82 to 10.88] for placebo versus 9.46% [8.47 to 10.46] for metformin) was not significant (p = 0.903). …”
  10. 1830
  11. 1831
  12. 1832
  13. 1833
  14. 1834
  15. 1835
  16. 1836
  17. 1837

    Mean SARS-CoV-2 viral load log 10 between groups. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
  18. 1838
  19. 1839
  20. 1840

    Increasing TPP side chain length decreases melanoma cell viability and clonogenic survival. by Kyle C. Kloepping (9928265)

    Published 2020
    “…The error bars for all data presented in Fig 2 represent the mean ± SEM. Results demonstrate that TPP derivatives decrease melanoma cell viability and clonogenic survival; and there is a structure-activity relationship between TPP side chain length and decreased viability and clonogenic survival.…”